Loading...
XWAR
GMT
Market cap18mUSD
Jul 10, Last price  
4.70PLN
1D
-0.21%
1Q
2.17%
IPO
-69.02%
Name

Genomtec SA

Chart & Performance

D1W1MN
XWAR:GMT chart
P/E
P/S
3,371.61
EPS
Div Yield, %
Shrs. gr., 5y
13.05%
Rev. gr., 5y
0.98%
Revenues
21k
+2,000.00%
152,71620,000219,00040,0001,0001,00021,000
Net income
-10m
L-6.93%
-1,446,800-10,939,000-7,115,000-11,928,000-9,013,000-11,208,000-10,431,000
CFO
-11m
L+69.51%
-1,694,362-2,515,000-5,528,000-3,787,000-7,952,000-6,716,000-11,384,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Genomtec S.A., established in 2016 and based in Wroclaw, Poland, is dedicated to the research, development, manufacturing, and global commercialization of advanced molecular diagnostic products. The company's expertise lies in optical systems and isothermal nucleic acid amplification methodologies. A core offering is Genomtec ID, a portable technological device designed for on-the-go genetic diagnostics. This system employs streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, fungi, and genetic mutations through the analysis of patient biological materials like swabs, urine, saliva, blood, and other bodily fluids. Furthermore, Genomtec has developed Genomtec Tumor, a SNAAT-based solution for identifying neoplastic mutations and those with prognostic value in cancer diagnoses. The company also offers diagnostic kits for COVID-19, including the Genomtec SARS-CoV-2 EvaGreen and Direct-RT-LAMP CE-IVD Kit, which detects SARS-CoV-2 RNA in samples from individuals suspected of infection, and the Genomtec RT-LAMP CE-IVD Duo-Kit, capable of identifying all variants of the SARS-CoV-2 virus.
IPO date
Mar 17, 2021
Employees
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT